接受左甲状腺素治疗的甲状腺功能减退女性心血管事件发生率:SWAN研究
本研究基于美国多中心纵向队列SWAN,纳入2647名中年女性,比较接受左甲状腺素(LT4)治疗的甲减女性与无甲状腺疾病女性从中年至老年前期的心血管事件风险。p=0.463),按基线TSH分层后亦无显著关联。
要点
- LT4治疗的甲减女性与无甲状腺疾病女性CVD事件风险无显著差异。
- LT4治疗组CVD事件7.8%,无甲状腺疾病组8.6%,p=0.616。
- 按基线TSH分层后,LT4治疗与CVD风险仍无显著关联。
核心结论
- 在长期随访至绝经过渡期的中年女性中,接受LT4治疗的甲减女性与无甲状腺疾病女性相比,CVD事件风险无显著差异。
研究设计与样本
- SWAN研究为美国7个地理站点开展的多中心纵向研究,纳入2647名中年女性,随访至多17次访视。
- 采用多变量Cox比例风险模型(时变暴露)分析LT4治疗与首次CVD事件的关系。
主要发现
- LT4治疗组421例(15.9%)中发生CVD事件33例(7.8%),无甲状腺疾病组发生191例(8.6%),p=0.616。
- 按基线TSH水平分层后,LT4治疗与CVD事件风险仍无显著关联。
关键数值与推荐
- 复合CVD结局定义为致死性或非致死性心肌梗死、卒中、心力衰竭、经皮冠状动脉介入治疗及冠状动脉旁路移植术。
临床怎么用
- 对于接受LT4治疗的甲减女性,本研究未观察到其CVD事件风险高于无甲状腺疾病女性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients treated for hypothyroidism with levothyroxine (LT4) monotherapy may be exposed to periods of excess and/or inadequate circulating thyroid hormone levels, which may increase the risk of cardiovascular disease (CVD). We hypothesized that the risk of CVD events in women treated with LT4 may be higher than in women without thyroid disease in the period from midlife to early old age. METHODS: The Study of Women's Health Across the Nation is a multisite longitudinal study of a diverse cohort of midlife women from seven geographic sites across the United States. Women were screened for a history of thyroid disease and the use of LT4. Each participant completed up to 17 follow-up visits during which the occurrence of CVD events was ascertained. The composite CVD outcome was defined as any of the following fatal or nonfatal events myocardial infarction, stroke, heart failure, percutaneous coronary intervention, and coronary artery bypass graft surgery. A multivariable Cox proportional hazards model with time-varying exposure was used to determine the relationship of LT4 treatment to the incidence of the first CVD event. A sensitivity analysis was conducted, stratifying the group with LT4 treatment by thyrotropin (TSH) level. RESULTS: Of the 2647 women who were included in the study, 421 (15.9%) received LT4 treatment during the study period. A total of 33 (7.8%) CVD events occurred in the group with LT4 treatment compared with 191 (8.6%) in the group without thyroid disease (p = 0.616). In the adjusted Cox proportional hazards model, there was no statistically significant relation of LT4 treatment to risk of CVD events (hazard ratio 0.85, confidence interval [0.55-1.31]; p = 0.463). No significant relation was identified after stratification by TSH level at baseline in the LT4 group. CONCLUSIONS: In a diverse sample of women with long-term follow-up through the menopause transition, we observed no difference in the risk of CVD events between women receiving LT4 treatment for hypothyroidism compared with women without thyroid disease.
引用
- Ettleson MD, Karavolos K, Burnett-Bowie SM, et al. The Incidence of Cardiovascular Disease Events in Women with Hypothyroidism: The Study of Women's Health Across the Nation. Thyroid. 2026. PMID: 41735798. doi:10.1177/10507256261425625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。